Braveheart Bio, Inc. (BRVE) stock price, financials & research

Regular session · ET · Market data may be delayed.

Company profile

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Travis Murdoch
Listed since: Aug 6, 2026
Employees: 49

Market position

Day range

Current $27.45

$26.22$28.90

52-week range

Current $27.45

$24.31$32.00

Open: $26.82
Previous close: $26.71
Volume: 550.67K; 1.25× average
Average volume: 440.63K; Average daily volume
Market cap: 1.94B USD
Beta: 0; Market reference 1
50-day average: $27.3482; +0.37% above average
200-day average: $27.3482; +0.37% above average

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$45.25

64.85% upside

Past 12 months12-month forecastHigh $48.00Average $45.25Low $40.00

BRVE news

globenewswire.comSep 16, 2026

Braveheart Bio to Participate in Stifel Cardiometabolic Forum

SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other…

Read source

globenewswire.comSep 8, 2026

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart…

Read source

globenewswire.comSep 1, 2026

Braveheart Bio to Participate in Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other…

Read source

fool.comAug 10, 2026

Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?

The transaction involved 27,777 shares acquired for ~$500,000 on August 7, 2026. The acquisition increased the total equity position by 5%, resulting in a 0.87% ownership stake.

Read source

fool.comAug 10, 2026

Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?

The transaction involved 83,333 shares with an estimated value of ~$1.5 million as of the August 7, 2026 market close. Director Viehbacher increased his direct equity holdings by 16% through this acquisition.

Read source

fool.comAug 10, 2026

Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?

Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.

Read source